Pharmacokinetics & Dosing

Mebendazole dosing in oncology is very different from routine anti-parasitic use, which is why the pharmacokinetic and clinical-trial context matters.

General dosing themes

The most relevant themes from the early oncology literature are:

• tolerated higher-dose use in cancer settings

• biomarker effects at standard safe oral doses in some studies

• the need to think in oncology-specific rather than household anti-parasitic terms

Clinical dosing signals

• A Phase 2a study found mebendazole was safe and well tolerated up to 4 g/day in cancer patients

• In metastatic colorectal cancer, 500 mg twice daily produced meaningful VEGF reduction and signal of response improvement after 12 weeks

Practical interpretation

The oncology discussion is not just What is the standard anti-parasitic dose? It is What dose is being explored for anti-cancer purposes, in what setting, and under what monitoring?

Key References

A phase 2a clinical study on the safety and efficacy of mebendazole in cancer
https://www.nature.com/articles/s41598-021-88433-y

Mebendazole in metastatic colorectal cancer: anti-VEGF effects at tolerated dose
https://www.sciencedirect.com/science/article/abs/pii/S0024320522002363